Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates
Portfolio Pulse from
Editas Medicine (EDIT) reported a Q4 loss of $0.55 per share, missing the Zacks Consensus Estimate of a $0.39 loss. This is a larger loss compared to $0.23 per share a year ago.
March 05, 2025 | 11:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Editas Medicine reported a larger-than-expected Q4 loss of $0.55 per share, missing the Zacks Consensus Estimate of $0.39. This marks an increase from the $0.23 loss per share a year ago.
The larger-than-expected loss and missing revenue estimates are likely to negatively impact Editas Medicine's stock price in the short term. The increase in loss per share compared to the previous year further adds to the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100